Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease

[1]  S. Schneeweiss,et al.  Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents , 2022, JAMA network open.

[2]  Toshiko Tanaka,et al.  A brain proteomic signature of incipient Alzheimer’s disease in young APOE ε4 carriers identifies novel drug targets , 2021, Science advances.

[3]  M. Link,et al.  American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity , 2021, Arthritis & rheumatology.

[4]  G. Cutter,et al.  Hydroxychloroquine for Primary Progressive Multiple Sclerosis , 2021, Annals of neurology.

[5]  Archana Mishra,et al.  Role of JAK/STAT in the Neuroinflammation and its Association with Neurological Disorders , 2021, Annals of neurosciences.

[6]  Mohammad Zaki Bin Ibrahim,et al.  Long‐term plasticity in the hippocampus: maintaining within and ‘tagging’ between synapses , 2021, The FEBS journal.

[7]  John F. Ouyang,et al.  Transcriptional signature in microglia associated with Aβ plaque phagocytosis , 2021, Nature Communications.

[8]  S. Schneeweiss,et al.  Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments , 2021, Endocrine reviews.

[9]  A. Brickman,et al.  Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis , 2021, BMJ.

[10]  D. Wang,et al.  Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications , 2020, Molecular neurobiology.

[11]  George Hripcsak,et al.  Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study , 2020, The Lancet Rheumatology.

[12]  F. Reggiori,et al.  Hydroxychloroquine in rheumatic autoimmune disorders and beyond , 2020, EMBO molecular medicine.

[13]  S. Sajikumar,et al.  Regulation of aberrant proteasome activity re‐establishes plasticity and long‐term memory in an animal model of Alzheimer's disease , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  S. Schneeweiss,et al.  Measuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the United States Medicare Data. , 2019, The journals of gerontology. Series A, Biological sciences and medical sciences.

[15]  Guoan Chen,et al.  Hydroxychloroquine suppresses lung tumorigenesis via inducing FoxO3a nuclear translocation through STAT3 inactivation. , 2020, Life sciences.

[16]  Moonseok Choi,et al.  Inhibition of STAT3 phosphorylation attenuates impairments in learning and memory in 5XFAD mice, an animal model of Alzheimer's disease. , 2020, Journal of pharmacological sciences.

[17]  S. Schneeweiss,et al.  Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study , 2020, Alzheimer's & dementia.

[18]  V. Zachariou,et al.  Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research , 2019, Biomedicines.

[19]  S. Lai,et al.  Chronic hydroxychloroquine exposure and the risk of Alzheimer’s disease , 2019, Annals of the Rheumatic Diseases.

[20]  D. Mango,et al.  Targeting Synaptic Plasticity in Experimental Models of Alzheimer’s Disease , 2019, Front. Pharmacol..

[21]  S. Schneeweiss,et al.  Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride , 2019, Diabetes Care.

[22]  S. Sajikumar,et al.  The p75 Neurotrophin Receptor Is an Essential Mediator of Impairments in Hippocampal-Dependent Associative Plasticity and Memory Induced by Sleep Deprivation , 2019, The Journal of Neuroscience.

[23]  S. Lovestone,et al.  Genetic and Real-World Clinical Data, Combined with Empirical Validation, Nominate Jak-Stat Signaling as a Target for Alzheimer’s Disease Therapeutic Development , 2019, Cells.

[24]  A. Halle,et al.  Inhibition of Stat3‐mediated astrogliosis ameliorates pathology in an Alzheimer's disease model , 2019, EMBO molecular medicine.

[25]  M. Mattson,et al.  Calcium dysregulation mediates mitochondrial and neurite outgrowth abnormalities in SOD2 deficient embryonic cerebral cortical neurons , 2018, Cell Death & Differentiation.

[26]  E. Perfetto,et al.  Predicting Diagnosis of Alzheimer’s Disease and Related Dementias Using Administrative Claims , 2018, Journal of managed care & specialty pharmacy.

[27]  I. Petersen,et al.  Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer’s disease: a population-based cohort study , 2018, Annals of the rheumatic diseases.

[28]  N. Reynolds,et al.  Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus , 2018, Lupus.

[29]  S. Sajikumar,et al.  Metaplasticity mechanisms restore plasticity and associativity in an animal model of Alzheimer’s disease , 2017, Proceedings of the National Academy of Sciences.

[30]  JA Rassen,et al.  Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases. , 2016, Clinical pharmacology and therapeutics.

[31]  Jason P. Fine,et al.  Statistical Primer for Cardiovascular Research Introduction to the Analysis of Survival Data in the Presence of Competing Risks , 2022 .

[32]  P. Cheah,et al.  Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain , 2016, Neural plasticity.

[33]  S. Sajikumar,et al.  Investigation of Synaptic Tagging/Capture and Cross-capture using Acute Hippocampal Slices from Rodents , 2015, Journal of visualized experiments : JoVE.

[34]  Sudha Seshadri,et al.  Development and validation of a brief dementia screening indicator for primary care , 2014, Alzheimer's & Dementia.

[35]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[36]  Jeremy A Rassen,et al.  Metrics for covariate balance in cohort studies of causal effects , 2014, Statistics in medicine.

[37]  H. Soininen,et al.  Validity of dementia and Alzheimer's disease diagnoses in Finnish national registers , 2014, Alzheimer's & Dementia.

[38]  D. Browning.  Pharmacology of Chloroquine and Hydroxychloroquine , 2014, Hydroxychloroquine and Chloroquine Retinopathy.

[39]  Richard Platt,et al.  A tool for assessing the feasibility of comparative effectiveness research , 2013 .

[40]  G. Collingridge,et al.  The role of JAK-STAT signaling within the CNS , 2013, JAK-STAT.

[41]  Abhi Shelat,et al.  One‐to‐many propensity score matching in cohort studies , 2012, Pharmacoepidemiology and drug safety.

[42]  Sebastian Schneeweiss,et al.  Multivariate‐adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases , 2010, Pharmacoepidemiology and drug safety.

[43]  G. Landreth,et al.  The role of microglia in amyloid clearance from the AD brain , 2010, Journal of Neural Transmission.

[44]  Zhenguo Wu,et al.  Tyk2/STAT3 Signaling Mediates β-Amyloid-Induced Neuronal Cell Death: Implications in Alzheimer's Disease , 2010, The Journal of Neuroscience.

[45]  J. Pontén,et al.  The ultrastructure of human and murine astrocytes and of human fibroblasts in culture. , 2009, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

[46]  Peter C Austin,et al.  Some Methods of Propensity‐Score Matching had Superior Performance to Others: Results of an Empirical Investigation and Monte Carlo simulations , 2009, Biometrical journal. Biometrische Zeitschrift.

[47]  J. Avorn,et al.  Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. , 2007, American journal of epidemiology.

[48]  Hilkka Soininen,et al.  Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study , 2006, The Lancet Neurology.

[49]  Sreedharan Sajikumar,et al.  Protein synthesis-dependent long-term functional plasticity: methods and techniques , 2005, Current Opinion in Neurobiology.

[50]  M. Bear,et al.  LTP and LTD An Embarrassment of Riches , 2004, Neuron.

[51]  Dominic M. Walsh,et al.  Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.

[52]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[53]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[54]  M Maclure,et al.  Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. , 2001, American journal of epidemiology.

[55]  P. Scheltens,et al.  Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study , 2001, The Lancet.

[56]  R Brookmeyer,et al.  Age-specific incidence rates of Alzheimer’s disease , 2000, Neurology.

[57]  D. Borchelt,et al.  Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins , 1997, Neuron.

[58]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[59]  R. Day,et al.  Bioavailability of hydroxychloroquine tablets in healthy volunteers. , 1989, British journal of clinical pharmacology.

[60]  A. Mackenzie,et al.  Pharmacologic actions of 4-aminoquinoline compounds. , 1983, The American journal of medicine.

[61]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[62]  Guy B. Williams,et al.  Genetic and Real-World Clinical Data , Combined with Empirical Validation , Nominate Jak-Stat Signaling as a Target for Alzheimer ’ s Disease Therapeutic Development , 2019 .

[63]  Sebastian Schneeweiss,et al.  Use of Health Care Databases to Support Supplemental Indications of Approved Medications , 2018, JAMA internal medicine.

[64]  Truls Østbye,et al.  The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited. , 2009, Journal of Alzheimer's disease : JAD.